Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers-Reference-Cited by-同舟云学术

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

Published:2007 Issue:6 Volume:28 Page:307-313
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Bergman Arthur,Mistry Goutam C.,Luo Wen-Lin,Liu Q.,Stone Julie,Wang Amy,Zeng Wei,Chen Li,Dilzer Stacy,Lasseter Kenneth,Herman Gary A.,Wagner John A.,Krishna Rajesh

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Reference9 articles.

1. (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

2. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

3. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

4. Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products;Diabetes Therapy;2022-12-16

2. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate;Journal of Pharmaceutical Sciences;2022-01

3. Dipeptidyl Peptidase 4 Inhibitors;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26

4. A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin;CPT: Pharmacometrics & Systems Pharmacology;2020-06

5. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers;Clinical Therapeutics;2018-10